MXCT — MaxCyte, Inc.

Summary of MaxCyte, Inc. Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $33 million for FY 2025, down 15% from $38.6 million in FY 2024.
• Q4 Revenue: $7.3 million, a 16% decline from $8.7 million in Q4 2024.
• Core Revenue: $6.8 million in Q4 2025 (down 22% YoY) and $29.6 million for the full year (down 9% YoY).
• Gross Margin: 78% in Q4 2025, an increase from 74% in Q4 2024.
• Operating Expenses: Reduced to $9 million in Q4 2025 from $19.3 million in Q4 2024, largely due to restructuring efforts.
• Cash Position: Ended 2025 with $155.6 million in cash and no debt.

2. Strategic Updates and Business Highlights

• Acquisition of SecurDx: Successfully integrated, with expectations for revenue growth in 2026.
• Launch of ExPERT DTX: A new modular electroporation platform aimed at enhancing early-stage drug discovery, expected to drive future revenue.
• SPL Agreements: 31 SPL agreements in total, with a focus on advancing clinical programs; 10 new SPLs signed in the last 24 months.
• Clinical Programs: 12 clinical programs supported across 11 SPL partners, with five expected to enter pivotal studies in the next 18 months.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected total revenue of $30 million to $32 million, with core revenue of $25 million to $27 million and $5 million from SPL program-related revenue.
• Q1 2026 Expectations: Anticipated to be the lightest quarter for core revenue, with a back-half weighted growth expected.
• Long-term Outlook: Optimism about the pipeline with several pivotal studies and potential commercial approvals in 2027 and 2028.

4. Bad News, Challenges, or Points of Concern

• Customer Consolidation: A 15% decline in purchases from the largest customer due to reorganization and inventory management.
• Revenue Headwinds: Approximately $4 million expected headwind in core revenue from lost SPL customers and program rationalization.
• Declining SPL Program-Related Revenue: Down to $3.4 million in 2025 from $6.1 million in 2024.
• Market Dynamics: Concerns about the overall trajectory of the business amidst improving industry conditions, with questions raised about potential loss of market share.

5. Notable Q&A Insights

• Customer Sentiment: Management emphasized that current challenges are not indicative of a fundamental deterioration in business but rather short-term headwinds.
• Future Growth Drivers: Confidence in the ExPERT DTX product and its potential to engage customers earlier in the research process.
• SPL Signings: Management remains optimistic about signing 3-5 new SPL agreements in 2026, with expectations for the first signing potentially in Q1.
• Market Demand: The management indicated that while capital spending is not currently affecting them, they expect an uptick in demand in the second half of 2026.

Overall, while MaxCyte faced significant challenges in 2025, including revenue declines and customer consolidation, the company remains optimistic about its strategic initiatives, particularly with new product launches and a strong cash position supporting future growth.